Filing Details

Accession Number:
0000899243-20-022644
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-17 21:40:35
Reporting Period:
2020-08-17
Accepted Time:
2020-08-17 21:40:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1060736 Seattle Genetics Inc SGEN Biological Products, (No Disgnostic Substances) (2836) 911874389
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741836 D Roger Dansey 21823 30Th Drive Se
Bothell WA 98021
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-17 13,192 $0.00 122,943 No 4 A Direct
Common Stock Disposition 2020-08-17 450 $157.79 122,493 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right to buy) Acquisiton 2020-08-17 636 $0.00 636 $161.82
Common Stock Non-Qualified Stock Option (right to buy) Acquisiton 2020-08-17 32,073 $0.00 32,073 $161.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
636 2030-08-17 No 4 A Direct
32,073 2030-08-17 No 4 A Direct
Footnotes
  1. These shares represent restricted stock units and will be settled in common stock upon vesting.
  2. Shares shall vest at a rate of 25% on each anniversary of August 15, 2020 until all shares are fully vested at the end of four years.
  3. Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 143 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on 7/31/2020.
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  5. Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date.